Haemophilias A and B
暂无分享,去创建一个
[1] P. Petrini,et al. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[2] J. Lusher. Inhibitors in young boys with haemophilia. , 2000, Bailliere's best practice & research. Clinical haematology.
[3] P. Giangrande,et al. Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] D. Dimichele,et al. Gene therapy ethics and haemophilia: an inevitable therapeutic future? , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] G. Dusheiko,et al. The natural history and antiviral treatment of hepatitis C in haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] J. Lusher. Early treatment with recombinant factor VIIa results in greater efficacy with less product , 1998, European journal of haematology. Supplementum.
[7] F. Rosendaal,et al. Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.
[8] K. Khair,et al. Complications experienced with central venous catheters in children with congenital bleeding disorders , 1997, British journal of haematology.
[9] K. Khair,et al. The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.
[10] E. Chen,et al. Characterization of the human factor VIII gene , 1984, Nature.
[11] J. Lusher,et al. Perinatal management of newborns with haemophilia , 2001, British journal of haematology.
[12] R. Ljung,et al. Anaphylactoid reactions and nephrotic syndrome – a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[13] V. Blanchette,et al. Central venous access catheters in children with haemophilia. , 1996, Blood Coagulation and Fibrinolysis.
[14] P. Giangrande,et al. Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders , 1999, British journal of haematology.
[15] D. DiMichele,et al. Inhibitors: resolving diagnostic and therapeutic dilemmas , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[16] R. Spicer,et al. Implanted vascular access devices (ports) in children: complications and their prevention , 2002, Pediatric Surgery International.
[17] A D Shapiro,et al. Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.
[18] E. Briët,et al. [Hemophilia B Leyden]. , 1982, Nederlands tijdschrift voor geneeskunde.
[19] C. Sabin,et al. Outcome of orthotopic liver transplantation in patients with haemophilia , 1998, Gut.
[20] F. Rodeghiero,et al. Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment. , 2001, Best practice & research. Clinical haematology.
[21] R. Miller,et al. Somatic gene therapy for haemophilia: Some counselling issues for today and tomorrow , 2002 .
[22] M. Ekman,et al. Tolerance induction using the Malmö treatment model 1982–1995 , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[23] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[24] Kessler,et al. Bleeding episodes in HIV‐positive patients taking HIV protease inhibitors: a case series , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[25] P. Mannucci,et al. A clinicopathological study of liver disease in haemophiliacs. , 1978, Journal of clinical pathology.
[26] Mannucci,et al. A prospective clinical trial of implantable central venous access in children with haemophilia , 1998, British journal of haematology.
[27] J. Craske,et al. AN OUTBREAK OF HEPATITIS ASSOCIATED WITH INTRAVENOUS INJECTION OF FACTOR-VIII CONCENTRATE , 1975, The Lancet.
[28] Wilde. Protease inhibitor therapy and bleeding , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[29] K. Fischer,et al. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[30] J. V. van Mourik,et al. Tissue Distribution of Factor VIII Gene Expression In Vivo – A Closer Look , 2001, Thrombosis and Haemostasis.
[31] Stylianos E. Antonarakis,et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A , 1993, Nature Genetics.
[32] H. Pettersson,et al. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.
[33] P. Giangrande,et al. The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993–2003 , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[34] M. Colombo,et al. Asymptomatic liver disease in haemophiliacs. , 1975, Journal of clinical pathology.
[35] Christof von Kalle,et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.
[36] M. Siimes,et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[37] R. Ljung,et al. Normal vaginal delivery is to be recommended for haemophilia carrier gravidae , 1994, Acta paediatrica.
[38] B. Cohen,et al. Commercial factor VIII associated hepatitis, 1974–75, in the United Kingdom: a retrospective survey , 1978, Journal of Hygiene.
[39] C. Kessler,et al. The molecular basis of haemophilia B , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[40] A. Widell,et al. Clinical spectrum of hepatitis C‐related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease , 2001, British journal of haematology.
[41] P. Green,et al. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. , 1993, Human molecular genetics.
[42] C. Hay,et al. PROGRESSIVE LIVER DISEASE IN HAEMOPHILIA: AN UNDERSTATED PROBLEM? , 1985, The Lancet.
[43] C. Sabin,et al. Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease , 1998, Journal of internal medicine.
[44] J. Goudemand,et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. , 2001, Best practice & research. Clinical haematology.
[45] J. Astermark,et al. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[46] B. Evatt,et al. Haemophilia 2002: emerging risks of treatment , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[47] P. Green,et al. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. , 2002, Blood.
[48] P. Mannucci,et al. Rare coagulation deficiencies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[49] Damiano,et al. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[50] D. Schaid,et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. , 1994, Human molecular genetics.
[51] C. Quinn,et al. Catheter-related deep venous thrombosis in children with hemophilia. , 2001, Blood.
[52] Ockelford,et al. The use of central venous catheters (portacaths) in children with Haemophilia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[53] C. Prowse,et al. Human Parvovirus B19 and Blood Products , 1997, Vox sanguinis.
[54] G. Buchanan. Factor concentrate prophylaxis for neonates with hemophilia. , 1999, Journal of pediatric hematology/oncology.
[55] H. Roehl,et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. , 2003, Blood.
[56] A. Miners,et al. Experience of prophylaxis treatment in children with severe haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[57] V. Blanchette,et al. Health‐related quality‐of‐life treatments for severe haemophilia: utility measurements using the Standard Gamble technique , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[58] J. Oldenburg,et al. NovoSeven® in immune tolerance therapy , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[59] E. Thorland,et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[60] K. Kurachi,et al. Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[61] Alan McClelland,et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.
[62] D. Treco,et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.
[63] H. Jürgens,et al. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study , 1999, European journal of pediatrics.
[64] C. Lee. Women and inherited bleeding disorders: menstrual issues. , 1999, Seminars in hematology.
[65] P. Petrini. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B , 2001 .
[66] Mannucci. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[67] C. Steer,et al. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides , 1998, Nature Medicine.
[68] Christine A. Lee,et al. Inhibitors in Patients with Haemophilia , 2002 .
[69] D. Jolly,et al. Animal Testing of Retroviral-Mediated Gene Therapy for Factor VIII Deficiency , 1999, Thrombosis and Haemostasis.
[70] H. Pettersson,et al. Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.
[71] C. Barnes,et al. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[72] F. Rosendaal,et al. The natural history of chronic hepatitis C in haemophiliacs , 1996, British journal of haematology.
[73] C. Mazurier,et al. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[74] C. Steer,et al. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[75] K. Pasi. Gene therapy for haemophilia , 2001, Bailliere's clinical haematology.
[76] P. Jones,et al. The early history of haemophilia treatment: a personal perspective , 2000, British journal of haematology.
[77] J. Gill,et al. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.
[78] E. Rodríguez‐Merchán. Common orthopaedic problems in haemophilia , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[79] D. Brettler. 8 Inhibitors in congenital haemophilia , 1996 .
[80] C. Kessler,et al. Management of haemophilia B patients with inhibitors and anaphylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[81] End-stage liver disease in persons with hemophilia and transfusion-associated infections. , 2002 .
[82] F. Beek,et al. Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.
[83] K. Pasi,et al. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate , 1996, British journal of haematology.
[84] M. Baiget,et al. Modifier genes in haemophilia: their expansion in the human genome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[85] P. Giangrande,et al. Treatment of haemophilia in the United Kingdom 1981-1996. , 2001 .
[86] F. Rodeghiero. von Willebrand disease: still an intriguing disorder in the era of molecular medicine , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[87] H. Roberts,et al. Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.